Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance

Justin R. Gregg, David Lopez, Chad Reichard, Jiali Zheng, Wenhui Wu, Yuanqing Ye, Brian Chapin, Jeri Kim, Carrie R. Daniel, John Davis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

PURPOSE: Active surveillance is increasingly used as a management strategy for localized prostate cancer. Coffee intake has been associated with a lower prostate cancer incidence. We assessed whether coffee was associated with disease progression in men on active surveillance. MATERIALS AND METHODS: A total of 411 patients with newly diagnosed Gleason score 6 or 7 prostate cancer were enrolled on a prospective active surveillance protocol for at least 6 months and completed a baseline dietary assessment. The active surveillance protocol included a biennial monitoring regimen with disease progression defined as an increase in the Gleason score. Cox proportional hazards models were used to evaluate associations of coffee intake with progression-free survival. We also evaluated patient genotype in the caffeine metabolism related single nucleotide polymorphism rs762551. RESULTS: Median followup was 36 months (range 6 to 126) and the Gleason score progressed in 76 of the 411 patients (18.5%). Compared to 0 cups per day, in the multivariable model adjusting for prostate specific antigen, patient age and tumor length, less than 1 cup (HR 0.85, 95% CI 0.40-1.71), 1 to 1.9 cups (HR 0.64, 95% CI 0.29-1.43), 2 to 3.9 cups (HR 0.71, 95% CI 0.35-1.47) and 4 cups or more (HR 1.67, 95% CI 0.81-3.45) were not significantly associated with progression-free survival (p for nonlinearity = 0.01). Patients with low/moderate coffee intake and the AA fast caffeine metabolizer genotype were less likely to experience grade progression than nonconsumers (HR 0.36, 95% CI 0.15-0.88, p = 0.03). CONCLUSIONS: Low to moderate coffee intake appears safe in men on active surveillance of localized prostate cancer. Further work is needed to determine whether high consumption is associated with shorter progression-free survival in sensitive groups.

Original languageEnglish (US)
Pages (from-to)308-314
Number of pages7
JournalThe Journal of urology
Volume201
Issue number2
DOIs
StatePublished - Feb 1 2019
Externally publishedYes

Fingerprint

Coffee
Caffeine
Disease Progression
Prostatic Neoplasms
Genotype
Neoplasm Grading
Disease-Free Survival
Prostate-Specific Antigen
Proportional Hazards Models
Single Nucleotide Polymorphism
Incidence
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance. / Gregg, Justin R.; Lopez, David; Reichard, Chad; Zheng, Jiali; Wu, Wenhui; Ye, Yuanqing; Chapin, Brian; Kim, Jeri; Daniel, Carrie R.; Davis, John.

In: The Journal of urology, Vol. 201, No. 2, 01.02.2019, p. 308-314.

Research output: Contribution to journalArticle

Gregg, Justin R. ; Lopez, David ; Reichard, Chad ; Zheng, Jiali ; Wu, Wenhui ; Ye, Yuanqing ; Chapin, Brian ; Kim, Jeri ; Daniel, Carrie R. ; Davis, John. / Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance. In: The Journal of urology. 2019 ; Vol. 201, No. 2. pp. 308-314.
@article{ca9603668bde43c08dadce8ec75e3d4b,
title = "Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance",
abstract = "PURPOSE: Active surveillance is increasingly used as a management strategy for localized prostate cancer. Coffee intake has been associated with a lower prostate cancer incidence. We assessed whether coffee was associated with disease progression in men on active surveillance. MATERIALS AND METHODS: A total of 411 patients with newly diagnosed Gleason score 6 or 7 prostate cancer were enrolled on a prospective active surveillance protocol for at least 6 months and completed a baseline dietary assessment. The active surveillance protocol included a biennial monitoring regimen with disease progression defined as an increase in the Gleason score. Cox proportional hazards models were used to evaluate associations of coffee intake with progression-free survival. We also evaluated patient genotype in the caffeine metabolism related single nucleotide polymorphism rs762551. RESULTS: Median followup was 36 months (range 6 to 126) and the Gleason score progressed in 76 of the 411 patients (18.5{\%}). Compared to 0 cups per day, in the multivariable model adjusting for prostate specific antigen, patient age and tumor length, less than 1 cup (HR 0.85, 95{\%} CI 0.40-1.71), 1 to 1.9 cups (HR 0.64, 95{\%} CI 0.29-1.43), 2 to 3.9 cups (HR 0.71, 95{\%} CI 0.35-1.47) and 4 cups or more (HR 1.67, 95{\%} CI 0.81-3.45) were not significantly associated with progression-free survival (p for nonlinearity = 0.01). Patients with low/moderate coffee intake and the AA fast caffeine metabolizer genotype were less likely to experience grade progression than nonconsumers (HR 0.36, 95{\%} CI 0.15-0.88, p = 0.03). CONCLUSIONS: Low to moderate coffee intake appears safe in men on active surveillance of localized prostate cancer. Further work is needed to determine whether high consumption is associated with shorter progression-free survival in sensitive groups.",
author = "Gregg, {Justin R.} and David Lopez and Chad Reichard and Jiali Zheng and Wenhui Wu and Yuanqing Ye and Brian Chapin and Jeri Kim and Daniel, {Carrie R.} and John Davis",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.juro.2018.08.048",
language = "English (US)",
volume = "201",
pages = "308--314",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance

AU - Gregg, Justin R.

AU - Lopez, David

AU - Reichard, Chad

AU - Zheng, Jiali

AU - Wu, Wenhui

AU - Ye, Yuanqing

AU - Chapin, Brian

AU - Kim, Jeri

AU - Daniel, Carrie R.

AU - Davis, John

PY - 2019/2/1

Y1 - 2019/2/1

N2 - PURPOSE: Active surveillance is increasingly used as a management strategy for localized prostate cancer. Coffee intake has been associated with a lower prostate cancer incidence. We assessed whether coffee was associated with disease progression in men on active surveillance. MATERIALS AND METHODS: A total of 411 patients with newly diagnosed Gleason score 6 or 7 prostate cancer were enrolled on a prospective active surveillance protocol for at least 6 months and completed a baseline dietary assessment. The active surveillance protocol included a biennial monitoring regimen with disease progression defined as an increase in the Gleason score. Cox proportional hazards models were used to evaluate associations of coffee intake with progression-free survival. We also evaluated patient genotype in the caffeine metabolism related single nucleotide polymorphism rs762551. RESULTS: Median followup was 36 months (range 6 to 126) and the Gleason score progressed in 76 of the 411 patients (18.5%). Compared to 0 cups per day, in the multivariable model adjusting for prostate specific antigen, patient age and tumor length, less than 1 cup (HR 0.85, 95% CI 0.40-1.71), 1 to 1.9 cups (HR 0.64, 95% CI 0.29-1.43), 2 to 3.9 cups (HR 0.71, 95% CI 0.35-1.47) and 4 cups or more (HR 1.67, 95% CI 0.81-3.45) were not significantly associated with progression-free survival (p for nonlinearity = 0.01). Patients with low/moderate coffee intake and the AA fast caffeine metabolizer genotype were less likely to experience grade progression than nonconsumers (HR 0.36, 95% CI 0.15-0.88, p = 0.03). CONCLUSIONS: Low to moderate coffee intake appears safe in men on active surveillance of localized prostate cancer. Further work is needed to determine whether high consumption is associated with shorter progression-free survival in sensitive groups.

AB - PURPOSE: Active surveillance is increasingly used as a management strategy for localized prostate cancer. Coffee intake has been associated with a lower prostate cancer incidence. We assessed whether coffee was associated with disease progression in men on active surveillance. MATERIALS AND METHODS: A total of 411 patients with newly diagnosed Gleason score 6 or 7 prostate cancer were enrolled on a prospective active surveillance protocol for at least 6 months and completed a baseline dietary assessment. The active surveillance protocol included a biennial monitoring regimen with disease progression defined as an increase in the Gleason score. Cox proportional hazards models were used to evaluate associations of coffee intake with progression-free survival. We also evaluated patient genotype in the caffeine metabolism related single nucleotide polymorphism rs762551. RESULTS: Median followup was 36 months (range 6 to 126) and the Gleason score progressed in 76 of the 411 patients (18.5%). Compared to 0 cups per day, in the multivariable model adjusting for prostate specific antigen, patient age and tumor length, less than 1 cup (HR 0.85, 95% CI 0.40-1.71), 1 to 1.9 cups (HR 0.64, 95% CI 0.29-1.43), 2 to 3.9 cups (HR 0.71, 95% CI 0.35-1.47) and 4 cups or more (HR 1.67, 95% CI 0.81-3.45) were not significantly associated with progression-free survival (p for nonlinearity = 0.01). Patients with low/moderate coffee intake and the AA fast caffeine metabolizer genotype were less likely to experience grade progression than nonconsumers (HR 0.36, 95% CI 0.15-0.88, p = 0.03). CONCLUSIONS: Low to moderate coffee intake appears safe in men on active surveillance of localized prostate cancer. Further work is needed to determine whether high consumption is associated with shorter progression-free survival in sensitive groups.

UR - http://www.scopus.com/inward/record.url?scp=85060013482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060013482&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2018.08.048

DO - 10.1016/j.juro.2018.08.048

M3 - Article

C2 - 30179617

AN - SCOPUS:85060013482

VL - 201

SP - 308

EP - 314

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -